KODIAK SCIENCES INC. Operating Expenses
KODIAK SCIENCES INC. (KOD) reported Operating Expenses of $66.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- KODIAK SCIENCES INC. operating expenses for the quarter ending 2026-06-30 was $66.84M, a 20.41% increase year-over-year.
- KODIAK SCIENCES INC. operating expenses for the quarter ending 2026-03-31 was $59.78M, a 1.19% increase year-over-year.
- KODIAK SCIENCES INC. operating expenses for the quarter ending 2025-12-31 was $57.45M, a 24.41% increase year-over-year.
- KODIAK SCIENCES INC. operating expenses for the quarter ending 2025-09-30 was $62.35M, a 33.71% increase year-over-year.
- KODIAK SCIENCES INC. operating expenses for fiscal 2025 was $234.39M, a 25.44% increase from fiscal 2024.
- KODIAK SCIENCES INC. operating expenses for fiscal 2024 was $186.85M, a 32.62% decline from fiscal 2023.
- KODIAK SCIENCES INC. operating expenses for fiscal 2023 was $277.32M, a 18.76% decline from fiscal 2022.
- KODIAK SCIENCES INC. operating expenses for fiscal 2022 was $341.38M, a 27.83% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $66.84M 10-Q · filed 2026-08-13 | $126.61M 10-Q · filed 2026-08-13 | $184.07M derived: sum of 3 quarters · filed 2026-08-13 | $246.42M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $59.78M 10-Q · filed 2026-05-07 | $117.23M derived: sum of 2 quarters · filed 2026-05-07 | $179.58M derived: sum of 3 quarters · filed 2026-05-07 | $235.09M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $57.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $119.81M derived: sum of 2 quarters · filed 2026-03-31 | $175.31M derived: sum of 3 quarters · filed 2026-08-13 | $234.39M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $62.35M 10-Q · filed 2025-11-13 | $117.86M derived: sum of 2 quarters · filed 2026-08-13 | $176.94M 10-Q · filed 2025-11-13 | $223.11M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $55.51M 10-Q · filed 2026-08-13 | $114.58M 10-Q · filed 2026-08-13 | $160.76M derived: sum of 3 quarters · filed 2026-08-13 | $207.39M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $59.07M 10-Q · filed 2026-05-07 | $105.25M derived: sum of 2 quarters · filed 2026-05-07 | $151.88M derived: sum of 3 quarters · filed 2026-05-07 | $199.87M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $46.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $92.81M derived: sum of 2 quarters · filed 2026-03-31 | $140.79M derived: sum of 3 quarters · filed 2026-03-31 | $186.85M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $46.63M 10-Q · filed 2025-11-13 | $94.61M derived: sum of 2 quarters · filed 2025-11-13 | $140.67M 10-Q · filed 2025-11-13 | $204.04M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-06-30 | $47.98M 10-Q · filed 2025-08-13 | $94.04M 10-Q · filed 2025-08-13 | $157.41M derived: sum of 3 quarters · filed 2026-03-31 | $211.91M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-03-31 | $46.05M 10-Q · filed 2025-05-14 | $109.43M derived: sum of 2 quarters · filed 2026-03-31 | $163.93M derived: sum of 3 quarters · filed 2026-03-31 | $248.76M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2023-12-31 | $63.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $117.87M derived: sum of 2 quarters · filed 2026-03-31 | $202.71M derived: sum of 3 quarters · filed 2026-03-31 | $277.32M 10-K · filed 2026-03-31 | ||
| 2023-09-30 | $54.50M 10-Q · filed 2024-11-14 | $139.33M derived: sum of 2 quarters · filed 2024-11-14 | $213.95M 10-Q · filed 2024-11-14 | $288.01M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-06-30 | $84.83M 10-Q · filed 2024-08-14 | $159.45M 10-Q · filed 2024-08-14 | $233.51M derived: sum of 3 quarters · filed 2025-03-27 | $312.99M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-03-31 | $74.61M 10-Q · filed 2024-05-15 | $148.68M derived: sum of 2 quarters · filed 2025-03-27 | $228.16M derived: sum of 3 quarters · filed 2025-03-27 | $320.23M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2022-12-31 | $74.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $153.54M derived: sum of 2 quarters · filed 2025-03-27 | $245.61M derived: sum of 3 quarters · filed 2025-03-27 | $341.38M 10-K · filed 2025-03-27 | ||
| 2022-09-30 | $79.48M 10-Q · filed 2023-11-14 | $171.55M derived: sum of 2 quarters · filed 2023-11-14 | $267.31M 10-Q · filed 2023-11-14 | $360.36M derived: sum of 4 quarters · filed 2024-03-28 | ||
| 2022-06-30 | $92.07M 10-Q · filed 2023-08-14 | $187.84M 10-Q · filed 2023-08-14 | $280.88M derived: sum of 3 quarters · filed 2024-03-28 | $348.42M derived: sum of 4 quarters · filed 2024-03-28 | ||
| 2022-03-31 | $95.77M 10-Q · filed 2023-05-15 | $188.82M derived: sum of 2 quarters · filed 2024-03-28 | $256.35M derived: sum of 3 quarters · filed 2024-03-28 | $312.26M derived: sum of 4 quarters · filed 2024-03-28 | ||
| 2021-12-31 | $93.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $160.58M derived: sum of 2 quarters · filed 2024-03-28 | $216.49M derived: sum of 3 quarters · filed 2024-03-28 | $267.05M 10-K · filed 2024-03-28 | ||
| 2021-09-30 | $67.53M 10-Q · filed 2022-11-09 | $123.44M derived: sum of 2 quarters · filed 2022-11-09 | $174.00M 10-Q · filed 2022-11-09 | $220.84M derived: sum of 4 quarters · filed 2023-03-28 | ||
| 2021-06-30 | $55.91M 10-Q · filed 2022-08-09 | $106.47M 10-Q · filed 2022-08-09 | $153.31M derived: sum of 3 quarters · filed 2023-03-28 | $189.97M derived: sum of 4 quarters · filed 2023-03-28 | ||
| 2021-03-31 | $50.56M 10-Q · filed 2022-05-10 | $97.40M derived: sum of 2 quarters · filed 2023-03-28 | $134.06M derived: sum of 3 quarters · filed 2023-03-28 | $160.84M derived: sum of 4 quarters · filed 2023-03-28 | ||
| 2020-12-31 | $46.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $83.50M derived: sum of 2 quarters · filed 2023-03-28 | $110.28M derived: sum of 3 quarters · filed 2023-03-28 | $136.01M 10-K · filed 2023-03-28 | ||
| 2020-09-30 | $36.66M 10-Q · filed 2021-11-09 | $63.44M derived: sum of 2 quarters · filed 2021-11-09 | $89.17M 10-Q · filed 2021-11-09 | $105.35M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $26.78M 10-Q · filed 2021-08-09 | $52.50M 10-Q · filed 2021-08-09 | $68.69M derived: sum of 3 quarters · filed 2022-03-01 | $81.42M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $25.72M 10-Q · filed 2021-05-10 | $41.91M derived: sum of 2 quarters · filed 2022-03-01 | $54.64M derived: sum of 3 quarters · filed 2022-03-01 | $66.45M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $16.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $28.92M derived: sum of 2 quarters · filed 2022-03-01 | $40.73M derived: sum of 3 quarters · filed 2022-03-01 | $49.19M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $12.73M 10-Q · filed 2020-11-09 | $24.55M derived: sum of 2 quarters · filed 2020-11-09 | $33.01M 10-Q · filed 2020-11-09 | $42.36M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $11.81M 10-Q · filed 2020-08-10 | $20.27M 10-Q · filed 2020-08-10 | $29.63M derived: sum of 3 quarters · filed 2021-03-01 | $36.01M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | $8.46M 10-Q · filed 2020-05-11 | $17.82M derived: sum of 2 quarters · filed 2021-03-01 | $24.20M derived: sum of 3 quarters · filed 2021-03-01 | $29.29M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $15.74M derived: sum of 2 quarters · filed 2021-03-01 | $20.83M derived: sum of 3 quarters · filed 2021-03-01 | $26.37M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $6.38M 10-Q · filed 2019-11-12 | $6.38K 10-Q · filed 2018-11-16 | $11.47M derived: sum of 2 quarters · filed 2019-11-12 | $17.02M 10-Q · filed 2019-11-12 | $17.02K 10-Q · filed 2018-11-16 | $42.52M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $5.09M 10-Q · filed 2019-08-14 | $10.64M 10-Q · filed 2019-08-14 | $36.14M derived: sum of 3 quarters · filed 2020-03-16 | $36.15M derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-03-31 | $5.55M 10-Q · filed 2019-05-15 | $31.05M derived: sum of 2 quarters · filed 2020-03-16 | $31.06M derived: sum of 3 quarters · filed 2020-03-16 | |||
| 2017-12-31 | $25.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $25.51M derived: sum of 2 quarters · filed 2020-03-16 | $25.52M 10-K · filed 2020-03-16 | |||
| 2017-09-30 | $3.98K 10-Q · filed 2018-11-16 | $15.76K 10-Q · filed 2018-11-16 | ||||
| 2016-12-31 | $17.15M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |